Rabbit Recombinant Monoclonal eIF4EBP1 phospho T37 + T46 antibody. Suitable for Flow Cyt, WB, IHC-P and reacts with Rat, Human, Mouse samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human EIF4EBP1 phospho T37 + T46.
IgG
Rabbit
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol (glycerin, glycerine), 49.88% PBS, 0.1% BSA
Liquid
Monoclonal
Flow Cyt | WB | IHC-P | |
---|---|---|---|
Human | Tested | Tested | Expected |
Mouse | Expected | Tested | Expected |
Rat | Tested | Expected | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info 0.001-1 µg/mL | Notes - |
Species Human | Dilution info 0.001-1 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 0.001 µg/mL | Notes - |
Species Human | Dilution info 0.001 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Repressor of translation initiation that regulates EIF4E activity by preventing its assembly into the eIF4F complex: hypophosphorylated form competes with EIF4G1/EIF4G3 and strongly binds to EIF4E, leading to repress translation. In contrast, hyperphosphorylated form dissociates from EIF4E, allowing interaction between EIF4G1/EIF4G3 and EIF4E, leading to initiation of translation. Mediates the regulation of protein translation by hormones, growth factors and other stimuli that signal through the MAP kinase and mTORC1 pathways.
Eukaryotic translation initiation factor 4E-binding protein 1, 4E-BP1, eIF4E-binding protein 1, Phosphorylated heat- and acid-stable protein regulated by insulin 1, PHAS-I, EIF4EBP1
Rabbit Recombinant Monoclonal eIF4EBP1 phospho T37 + T46 antibody. Suitable for Flow Cyt, WB, IHC-P and reacts with Rat, Human, Mouse samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human EIF4EBP1 phospho T37 + T46.
IgG
Rabbit
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol (glycerin, glycerine), 49.88% PBS, 0.1% BSA
Liquid
Monoclonal
4EB1T37T46-A5
Affinity purification Protein A/G
kappa
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This supplementary information is collated from multiple sources and compiled automatically.
EIF4EBP1 also known as 4EBP1 or p4EBP1 is an important protein that acts as a translational repressor by binding to eIF4E therefore inhibiting cap-dependent translation. The molecular weight of 4EBP1 is approximately 12 kDa. This protein is ubiquitously expressed in various tissues indicating its widespread involvement in cellular functions. eIF4EBP1 can be detected and quantified using techniques like the eIF4EBP1 ELISA making it a common target in research for its role in translation regulation.
EIF4EBP1 plays an important role in regulating cell growth and proliferation by modulating protein synthesis. It is a part of the eIF4F complex which is responsible for the initiation of mRNA translation. When hypophosphorylated eIF4EBP1 binds tightly to eIF4E and prevents the assembly of the active eIF4F complex leading to reduced translation initiation of mRNAs involved in growth and survival. This regulation is important in conditions where cells need to adapt to metabolic stress or external signals.
The mammalian target of rapamycin (mTOR) pathway regulates eIF4EBP1 through phosphorylation. In response to growth signals mTOR phosphorylates eIF4EBP1 causing the release of eIF4E and allowing mRNA translation to proceed. This interaction links eIF4EBP1 to the PI3K/AKT/mTOR signaling pathway which influences cell cycle progression and survival. Related proteins in this pathway include ribosomal protein S6 kinase (S6K1) which is also phosphorylated by mTOR to promote protein synthesis.
Deregulation of eIF4EBP1 has been implicated in cancer and neurological disorders. In cancer hyperactive mTOR signaling can lead to excessive phosphorylation of 4EBP1 decreasing its ability to inhibit eIF4E and enhancing translation of oncogenic proteins. In neurological disorders imbalanced eIF4EBP1 activity can disrupt synaptic plasticity and memory formation. Proteins such as p70S6K which are also part of the mTOR pathway share connections with eIF4EBP1 in these pathological conditions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Flow cytometric analysis of Jurkat cells secondary antibody only negative control (blue) or treated with LY294002 + U0126 + wortmanmin (red) or with FBS (green) using 0.1 ug/mL of ab278686.
Flow cytometric analysis of C6 cells untreated cells stained with secondary antibody as negative control (blue) or untreated (red) or treated with UV and TPA (green) and stained using ab278686 at 0.1µg/mL.
Peptide blocking flow cytometric analysis of Jurkat cells LY294002 plus wortmannin plus U0126 LWU) treated cells stained with secondary antibody as negative control (light blue) or treated with LWU (red) or treated with FBS (green) or LUW and blocked with phospho-peptide (black) or FBS and blocked with phospho peptide (gold) or LUW and blocked with non-phospho peptide (dark blue) or FBS and blocked with non-phospho peptide (purple) using ab278686 at 0.1μg/mL.
All lanes: Western blot - Anti-eIF4EBP1 (phospho T37 + T46) antibody [4EB1T37T46-A5] (ab278686) at 0.001 µg/mL
Lane 1: K562 cell extract untreated
Lane 2: K562 cell extract treated with imatinib
Predicted band size: 13 kDa
All lanes: Western blot - Anti-eIF4EBP1 (phospho T37 + T46) antibody [4EB1T37T46-A5] (ab278686) at 0.001 µg/mL
Lane 1: NIH3T3 cell extract untreated
Lane 2: NIH3T3 cell extract treated with PDGF
Predicted band size: 13 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com